2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Artificial Intelligence (AI), Machine Learning, Biological Processes, Immune Mechanism, Molecular Biology, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Value, Diseases, Bleeding and Clotting, Immunology, Infectious Diseases, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1616 Secondary cytogenetic abnormalities identify an older CBF-AML subgroup with comparable outcomes following venetoclax-based therapy versus intensive chemotherapy

Xin Wang, MD, MSCE, Quynh Long Khuong, MD, MS2, Daniel J. Zheng, MD, MHS, MSHP3, Alexis Chen Boulter, MD4, Kelly Diringer Getz, PhD, MPH5
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
4 Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States

Introduction: Intensive chemotherapy (IC) remains the standard induction therapy for patients with core-binding factor acute myeloid leukemia (CBF-AML). Most data on CBF-AML are from younger patients; however, those data are often extrapolated to the elderly population, who are known to harbor fundamentally distinct genomic features and have lower tolerability to IC. Despite high remission rates, elderly patients treated with IC have reported 5-year overall survival (OS) of only 30–40% and non-relapse mortality (NRM) up to 25%. Although many clinicians have adopted venetoclax/hypomethylating agent (VEN/HMA) into the treatment for older/frail patients with CBF-AML, comparative effectiveness data are lacking. Further, whether specific genomic subsets derive differential benefits is unknown. In this study, we aim to compare the real-world outcomes between VEN/HMA and IC and determine whether baseline genomic features modify treatment effect.  

Methods: Adult patients ≥65 years of age from Flatiron Health, a nationwide, electronic health record-derived, de-identified database, with confirmed new CBF-AML, defined as documented positivity of t(8;21) and/or inv(16) within ±45 days of the time of diagnosis, from January 2017 to October 2024, and received either VEN/HMA or IC as induction therapy were included. OS was defined as time from induction initiation to death. Event-free survival (EFS) was defined as time from induction initiation to induction failure, relapse or death. Survival outcomes were compared using Kaplan-Meier estimates and Cox regression with inverse probability weighting to balance baseline demographic, clinical, and genomic features. All cause 30- and 60-day mortality rate and prevalence of severe infectious complications, defined as severe sepsis, septic shock, bacterial or invasive fungal infection, or documented administration of non-prophylactic antimicrobials, within the first 6 months of therapy were described and compared using modified Poisson regression considering death as a competing event.  

Results: A total of 210 patients were included (125 VEN/HMA, 85 IC). Patients treated with VEN/HMA were older (median age 75 vs. 69), less likely to have concurrent KIT or FLT3-ITD mutation(s) (7.2% vs. 21.2%), and more likely to have secondary cytogenetic abnormalities (71.2% vs. 43.5%), particularly adverse-risk cytogenetics (49.6% vs. 17.6%) compared to IC group. At a median follow-up of 31 months, patients treated with VEN/HMA had worse OS compared to those treated with IC (2-yr OS rate 19.7% (13.0–29.7) vs. 53.4% (43.1–66.1)), even after adjusting for measured confounders (adjusted HR (aHR) 1.89 (1.25-2.86)). NRM was higher in VEN/HMA compared to IC group (2-yr NRM rate 50.5% vs. 19.9%, aHR 2.24 (1.17-4.28)), despite significantly fewer severe infections (12.8% vs. 31.8%, adjusted relative risk (aRR) 0.38 (0.21-0.70)). The 30-day (7.2% vs. 4.7%; aRR 0.92 (0.29-2.90)) and 60-day mortality rates (18.4% vs. 10.6%; aRR 1.39 (0.65-2.98)) were similar between the two groups. Differences in survival outcomes between VEN/HMA and IC were consistent across inv(16) and t(8;21) subgroups.  

Baseline secondary cytogenetic abnormalities appeared to modify treatment effect.  Inferior OS with VEN/HMA was observed across most subgroups but not among those with secondary cytogenetic abnormalities (aHR 1.35 (0.79-2.31)), especially adverse-risk cytogenetics (aHR 0.89 (0.46-1.71)). Notably, among patients with del(17), VEN/HMA was associated with superior OS compared to IC (aHR 0.33 (0.14-0.78)). When examining relapse-related outcomes, patients with adverse-risk cytogenetics had numerically more favorable EFS when treated with VEN/HMA (aHR 0.60 (0.29-1.22)) and similar NRM (aHR 1.21 (0.40-3.67)) relative to IC. Risk of severe infections was also lower with VEN/HMA among those with secondary cytogenetic abnormalities (11.1% vs. 27.1%; aRR 0.39 (0.19-0.81)). 

Conclusions: Secondary cytogenetic abnormalities, particularly adverse-risk features, are prevalent in elderly patients with CBF-AML. VEN/HMA is commonly used in the real-world setting for elderly patients with CBF-AML. Although VEN/HMA was associated with inferior survival overall, treatment effects differed according to baseline cytogenetic risk features. Among patients with secondary cytogenetic abnormalities, VEN/HMA achieved comparable survival with lower infectious toxicity, supporting further prospective evaluation of genomically informed treatment selection.  

Xin Wang, MD, MSCE: No relevant conflicts of interest to declare.